top of page
Nuevocor_Assets_Size 1 copy 7_2x.png

Team

Nuevocor_R2-Revisions.png

Management Team

Yann Chong TAN, PhD

Founding CEO

Co-founded multiple biotech companies which collectively raised more than $400M in funding with successful IPO exit, in which he held various C-suite roles including that of Chief Scientific Officer.

Robert PIPERNO

Senior Vice President,
Tech Ops

Extensive CMC, Manufacturing, and Quality experience in the pharmaceutical and biopharmaceutical industries for clinical and commercial gene therapies.

Christian BECK, PhD

Vice President,
Corporate Development

Unique experience in corporate finance, strategy and business development with biopharma transaction experience gained at global investment banks and a biopharma company.

John LEE, MD, PhD

Chief Medical Officer

Board-certified cardiologist with extensive clinical development expertise in both pharma and biotech companies and led clinical development programs of a public biotech from Phase I-III.

Cheryl LEE

Vice President,
Operations

Experienced life science operator and finance leader with more than 15 years of operational experience.

Board of Directors

Mia HU, PhD

Board Member

Boehringer Ingelheim Venture Fund

KHOO Shih, PhD

Board Member

ClayvstBio

Advisors

Brian BURKE, PhD

Co-Founder and Advisor

Former Research Director at the Agency for Science, Technology and Research, Singapore.

Distinguished cell biologist in the area of the nuclear envelope, including lamins and the LINC complex through the innovative use of microscopic and biochemical technologies.

Colin STEWART, PhD

Co-Founder and Advisor

Former Research Director at the Agency for Science, Technology and Research, Singapore.

Pioneer in techniques underpinning mouse experimental genetics, and developer of multiple mouse models for laminopathies for elucidating mechanisms of disease.

W James NELSON, PhD

Advisor

Professor Emeritus at Stanford University.

Eminent cell biologist with seminal contributions in mechanobiology, membrane trafficking and cellular organization.

Mark KAY, MD, PhD

Co-Founder and Advisor

Head of the Division of Human Gene Therapy; and Professor of Pediatrics and Genetics at Stanford University.

World expert in the area of gene therapy technologies for the treatment of genetic and acquired diseases, including the discovery of novel adeno-associated virus (AAV) capsids.

Clinical Trial Steering Committee

Deepak BHATT, MD, MPH, MBA

Clinical Trial Steering Committee Member

Director of Mount Sinai Heart;
Dr. Valentin Fuster Professor of Cardiovascular Medicine at Icahn School of Medicine at Mount Sinai; Member of Board of Directors at Bristol Myers Squibb.

Neal LAKDAWALA, MD

Clinical Trial Steering Committee Member

Cardiovascular genetics specialist at Brigham and Women’s Hospital; Assistant Professor at Harvard Medical School.

Calum MACRAE, MD, PhD

Clinical Trial Steering Committee Member

Vice Chair for Scientific Innovation in the Department of Medicine at Brigham and Women’s Hospital; Professor of Medicine at Harvard Medical School.

bottom of page